A ketogenic diet — which involves eating a very low amount of carbohydrates and replacing them with fat — may help ease fatigue, improve neurological function, and boost life quality in people with multiple sclerosis (MS), according to a new analysis. Researchers stressed that available data on the effects…
A new positron emission tomography (PET) tracer may help determine the extent of nerve fiber loss in multiple sclerosis (MS) lesions, something that can’t be identified with conventional MRI imaging, according to a new study. Researchers think the new imaging tech could help track the efficacy of experimental therapies…
Medications that can promote the repair of the myelin sheath — the protective coating around nerve cells in the body — may also help limit nerve damage in multiple sclerosis (MS), according to a new analysis of data from a small clinical trial testing an anticancer therapy called bexarotene…
A type of imaging finding called iron rim lesions are associated with more severe disability and a greater extent of brain damage in people with multiple sclerosis (MS), a new analysis suggests. This specific imaging finding may help guide discussions about individualized treatments for MS, the study’s researchers said.
Over the past three decades, the number of adults worldwide being diagnosed with multiple sclerosis (MS) has increased, but globally, rates of death related to complications of MS have declined, a new study shows. “The period from 1990 to 2021 has witnessed important shifts in the global landscape of…
Multiple sclerosis (MS) may increase the risk of developing Alzheimer’s disease, according to a new analysis of genetic data. The findings indicate genetic changes that influence the activity of immune T-cells may play a role in both MS and Alzheimer’s. The study, “Multiple sclerosis…
Fenebrutinib significantly reduced the occurrence of new brain lesions with active inflammation in people with relapsing multiple sclerosis (MS), a Phase 2 clinical trial found. In the open-label extension portion of the FENopta trial (NCT05119569), disease activity “remained very low” for nearly one year, researchers wrote, with 98%…
People with multiple sclerosis (MS) who are treated with formulations of botulinum toxin to manage spasticity generally report being satisfied with the treatment, a new study reports. The study examined the use of these formulations in people with spasticity due to a number of conditions, the most common…
A team of U.S. and Chinese researchers appears to have unlocked a novel way to stop T-cells from attacking the body in multiple sclerosis (MS) and other autoimmune diseases, according to the findings of a new study. An experimental therapy called BiTS, developed based on these new molecular insights,…
Anti-CD20 therapies, a type of treatment approved for multiple sclerosis (MS), alter the activity of several types of immune cells, including increasing the levels of certain anti-inflammatory immune cells. That’s according to the study “Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell…
A new imaging technology may help detect early signs of brain damage in people with multiple sclerosis (MS) that aren’t visible on conventional MRI scans, a recent study shows. The technology detects specific metabolic alterations in the brain by tracking certain metabolites and neurotransmitters — molecules that nerve…
More than 90% of relapsing-remitting multiple sclerosis (RRMS) patients who received Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium have not experienced confirmed disability worsening after nearly three years. That’s according to new data from the EMPhASIS Phase 2 clinical trial (NCT03846219) and its open-label extension (OLE)…
A CAR T-cell therapy from Iaso Biotherapeutics was tolerated well and led to marked improvements in disability for three people with progressive forms of multiple sclerosis (MS), according to early data from a Phase 1 clinical trial. After a single dose of equecabtagene autoleucel, patients saw rapid and…
In people with benign relapsing-remitting multiple sclerosis (RRMS) who have minimal disease activity, there is a loss of overall brain tissue but specific parts of the brain may grow to help compensate for the damage, a new study indicates. The study, “AI-driven MRI analysis reveals brain…
Hormone therapies used in gender-affirming care for transgender people may affect disease activity in multiple sclerosis (MS), a small new study reports, although its researchers cautioned that more research is are needed to more comprehensively assess its impact in MS. The study, “Gender-affirming interventions and prognosis…
Children with pediatric-onset multiple sclerosis (POMS) experience biological aging at a faster rate than children without the disease, a study shows. “We found evidence that children living with MS experience accelerated biological aging,” Jennifer Graves, MD, PhD, senior author of the study at the University of California, San Diego,…
Infections and stressful life events in childhood may increase the risk of developing multiple sclerosis (MS), while childhood exercise is associated with lower MS risk, according to a study. The findings, part of the German National Cohort (NAKO) population study, imply that programs to encourage physical activity and prevent…
Pro-inflammatory signaling molecules that have been implicated in multiple sclerosis (MS) cause problems with the growth and development of myelin-making cells in the brain, according to a study done in cell models. The findings may have implications for treating MS, as promoting the growth of myelin-making cells could be…
People who experience adversity during childhood, such as abuse or neglect, may be at increased risk of multiple sclerosis (MS) and other autoimmune diseases, but available data that supports this association is generally low quality, a study reports. “Drawing concrete treatment recommendations is premature, given the low certainty of…
The Epstein-Barr virus (EBV) — a well-established risk factor for multiple sclerosis (MS) — is able to alter the movements of infected immune cells, a new study reveals. The findings shed new light on how EBV may set the stage for MS to develop, and could potentially form…
Tysabri (natalizumab), an approved treatment for forms of multiple sclerosis (MS), can be safely used during pregnancy or while breastfeeding, a study showed. “The findings of our observational study offer … relevant insight into the safety profile of [Tysabri] therapy not only during pregnancy but also during breastfeeding,”…
Treatment with masitinib, an experimental therapy being developed by AB Science for progressive forms of multiple sclerosis (MS), reduced markers of nerve damage and inflammation and slowed disease progression in a mouse model of MS. “This study is the first to demonstrate that masitinib can lower serum NfL…
Quantum Biopharma intends to ask the U.S. Food and Drug Administration (FDA) this year for permission to start a Phase 2 clinical trial testing Lucid-21-302, its novel therapy for promoting myelin repair, in people with multiple sclerosis (MS). The company announced that it has completed dosing in a…
Elevated levels of two bacterial strains from the Lachnospiraceae family in the gut may be a key risk factor for multiple sclerosis (MS), according to a study. The study, “Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree…
The U.S. Food and Drug Administration (FDA) has approved a new generic form of glatiramer acetate injection, a treatment for relapsing forms of multiple sclerosis (MS) that was originally approved under the brand name Copaxone. The generic was developed by Zydus Lifesciences in collaboration with Chemi S.p.A.,…
In people with relapsing forms of multiple sclerosis (MS) treated with Ocrevus (ocrelizumab), levels of B-cells can help to predict the risk of progression independent of relapse activity, a new study reports. “Our results unveil a discernible relationship between the degree of B-cell depletion and disease progression in…
People with multiple sclerosis (MS) who experience progression independent of relapse activity (PIRA) tend to have greater damage to major white matter tracts, or bundles of nerve fibers that connect different regions of the brain, a new study reports. The findings offer some insights into the biological processes that…
Foralumab was well tolerated in people with nonactive secondary progressive multiple sclerosis (SPMS), according to data from a small, open-label study conducted under an expanded access program. The therapy, being developed by Tiziana Life Sciences, also eased fatigue and lessened disability in some participants. The promising findings formed…
Certain lesions in the spinal cords of people with multiple sclerosis (MS) show damage to nerve fibers despite having normal myelin, according to a study done on postmortem samples using powerful MRI scans paired with detailed tissue analyses. The identification of these lesions “provides a novel opportunity to detect…
Wider rims of immune cells surrounding multiple sclerosis (MS) lesions in the brain and spinal cord are associated with faster disease progression, a new study shows. Monitoring this type of lesion may help track MS disease progression and measure how the disease is responding to treatment, and the…
Get regular updates to your inbox.
